Claims for Patent: 9,505,827

Summary for Patent: 9,505,827

Title:	Animal models and therapeutic molecules
Abstract:	The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanized antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.
Inventor(s):	Bradley; Allan (Cambridge, GB), Lee; E-Chiang (Cambridge, GB), Liang; Qi (Cambridge, GB), Wang; Wei (Cambridge, GB), Friedrich; Glenn (Cambridge, GB)
Assignee:	Kymab Limited (Cambridge, GB)
Application Number:	13/740,727
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,505,827
Patent Claims:	1. A transgenic mouse having a germline with a homozygous immunoglobulin heavy chain (IgH) locus comprising unrearranged human IgH variable region gene segments comprising Vs, Ds and Js at an endogenous locus operatively linked to an IgH constant (C) region comprising an endogenous C segment at an IgH locus; wherein said homozygous IgH locus comprises in 5' to 3' transcriptional orientation said unrearranged human Vs, Ds and Js comprising a 3' JH gene segment, a human/mouse chimeric DNA junction, an enhancer, and said operatively linked C region; wherein said homozygous chimeric IgH locus comprises a chimeric J/C intron comprising human DNA downstream of and naturally contiguous with said 3' JH gene segment, said human DNA being contiguous with mouse J/C intronic DNA upstream of said enhancer, and wherein said human DNA joins said mouse J/C intronic DNA at said human/mouse chimeric junction within said J/C intron, wherein DNA between said 3' human JH segment and said human/mouse chimeric DNA junction is less than 2 kb, said germline comprising all or part of mouse IgH variable region DNA; wherein said homozygous IgH locus of said mouse is capable of undergoing V, D, J joining; wherein said transgenic mouse is capable, upon stimulation with antigen, of producing antibody comprising a chimeric Ig heavy chain comprising a human IgH variable region; and wherein said transgenic mouse is capable of breeding with a second transgenic mouse, said second transgenic mouse having a germline with a homozygous IgH locus comprising unrearranged human IgH variable region gene segments operatively linked to an IgH constant (C) region comprising an endogenous C segment of an IgH locus to provide subsequent generation mice, wherein a said subsequent generation mouse comprises: (a) in its germline an homozygous IgH locus comprising unrearranged human IgH variable region gene segments operatively linked to an IgH constant (C) region comprising an endogenous C segment of an IgH locus, and (b) in its germline all or part of mouse IgH variable region DNA; and (c) wherein said IgH locus of said subsequent generation mouse is capable of undergoing V, D, J joining; (d) wherein said subsequent generation mouse is capable, upon stimulation with antigen, of producing antibody comprising a chimeric Ig heavy chain comprising a human IgH variable region; and (e) is capable of breeding with a mouse having a germline with a homozygous IgH locus comprising unrearranged human IgH variable region gene segments operatively linked to an IgH constant (C) region comprising an endogenous C segment of an IgH locus to provide further subsequent generation mice. 2. The mouse of claim 1, wherein said mouse J/C intronic DNA at said human/mouse chimeric junction and upstream of said enhancer comprises 129 mouse strain DNA, and wherein said enhancer is a mouse 129 strain .mu. enhancer. 3. The transgenic mouse of claim 1, wherein DNA between said 3' human JH gene segment and said human/mouse chimeric DNA junction is less than 1 kb. 4. The mouse of claim 1, wherein said C gene segment comprises a mouse C.mu. segment. 5. The transgenic mouse of claim 1, wherein said all or part of said mouse IgH variable region DNA is away from its native position in an IgH locus. 6. The transgenic mouse of claim 5, wherein said all or part of said mouse IgH variable region DNA is inverted with respect to its native chromosomal orientation and upstream of said human variable region gene segments. 7. The transgenic mouse of claim 2, wherein said unrearranged human VH gene segments are in the place of endogenous mouse Ig VH region segment(s) upstream of said enhancer. 8. The transgenic mouse of claim 2, wherein said unrearranged human DH gene segments are in the place of endogenous mouse Ig DH gene segment(s) upstream of said enhancer. 9. The transgenic mouse of claim 2, wherein said unrearranged human JH gene segments are in the place of endogenous mouse Ig JH gene segment(s) upstream of said enhancer. 10. The transgenic mouse of claim 1, wherein said human DNA contiguous with said human 3' JH gene segment comprises 400 base pairs of human JC intron DNA.

Details for Patent 9,505,827

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2029-07-08
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2029-07-08
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2029-07-08